Teleflex has obtained market clearance from the US Food and Drug Administration (FDA) for its Arrow Seldinger arterial catheterisation device.

Indicated for short-term use, the Seldinger device is developed to eliminate the confusion of catheter identification, minimise complications risk associated with insertion, and offer an optimal diagnostic method for enhanced patient safety and effective treatment.

Expected to be commercially launched in the country’s market this year, the catheterisation device is available in various sizes to allow customisation based on patient, insertion site and application.

Teleflex Vascular Access division vice-president and general manager Jake Newman said: “As we continue to discover new and innovative solutions, the Seldinger arterial catheterisation device is now part of our extensive arterial offering in the US market.

"This innovative device is intended to facilitate ease of insertion and resistance to body collapse."

"This innovative device is intended to facilitate ease of insertion and resistance to body collapse."

The firm develops medical technology solutions for vascular and interventional access, surgical, anaesthesia, cardiac care, urology, emergency medicine, and respiratory care sectors.

Teleflex’s Arrow brand includes technically advanced vascular access devices with antimicrobial and antithrombogenic protection to avoid vascular-related complications.

The range offers long and short dwell central venous catheters (CVC), sheath introducers, arterial lines, peripherally inserted central catheters (PICC), devices for intraosseous vascular access, and vascular positioning system for placement of a PICC or CVC near the heart.

In addition to arterial products with the Seldinger technique, the brand comprises products with Smooth Needle Placement, Extension set, Suture Wings and Improved Guidewire.